Author

Wei Liu

Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, State Key Laboratory of Experimental Hematology

Observed institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, State Key Laboratory of Experimental Hematology

ORCID: 0000-0002-0448-7210

Observed ORCIDs: 0000-0002-0448-7210, 0000-0003-4713-2441

OpenAlex ID: A5128897375

Phase 1 pilot study for hemophilia-A: AAV8 vector with prophylactic tacrolimus-glucocorticoid achieves therapeutic FVIII activity

2026 · Wei Liu, Xiaolei Pei, et al. · Signal Transduction and Targeted Therapy · 4

Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial

2026 · Yunfei Chen, Zhengjie Hua, et al. · EClinicalMedicine · 3

Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after the BTK inhibitor era

2026 · Yuting Yan, Weihao Chen, et al. · Leukemia · 1

Sequence-based artificial intelligence-guided inhibitory peptides to counteract AAV neutralizing antibodies in gene therapy.

2026 · Bingqi Xu, Xin Zhang, et al. · PubMed

Innovations in Haemostasis Management in China: From Gene Therapy to Novel Rebalancing Strategies

2026 · Wei Liu, Xiao Xiao, et al. · Haemophilia

Abstract 5051: A multi-center hospital-based case-control study of lymphoid and myeloid neoplasms (AsiaLymph): Study design and initial findings for education, body mass index, and family history

2026 · Qing Lan, Lauren M. Hurwitz, et al. · Cancer Research

Sequence-based artificial intelligence-guided inhibitory peptides to counteract AAV neutralizing antibodies in gene therapy

2025 · Bingqi Xu, Xin Zhang, et al. · Molecular Therapy Advances

Works count: 7

Citation count: 8

H-index: 2

I10-index: